HitGen Future Growth

Future criteria checks 3/6

HitGen is forecast to grow earnings and revenue by 22% and 19.5% per annum respectively. EPS is expected to grow by 20.1% per annum. Return on equity is forecast to be 4.6% in 3 years.

Key information

22.0%

Earnings growth rate

20.1%

EPS growth rate

Life Sciences earnings growth	29.1%
Revenue growth rate	19.5%
Future return on equity	4.6%
Analyst coverage	Low
Last updated	02 Sep 2024

Recent future growth updates

Recent updates

Optimistic Investors Push HitGen Inc. (SHSE:688222) Shares Up 51% But Growth Is Lacking

Oct 08

HitGen Inc. (SHSE:688222) Shares Could Be 26% Above Their Intrinsic Value Estimate

Jul 03

HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly

Jun 06

HitGen Inc.'s (SHSE:688222) 28% Jump Shows Its Popularity With Investors

Mar 07

Earnings and Revenue Growth Forecasts

SHSE:688222 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	613	79	57	117	2
12/31/2025	506	62	42	80	2
12/31/2024	437	51	23	61	2
6/30/2024	410	45	111	170	N/A
3/31/2024	409	64	103	146	N/A
12/31/2023	371	41	71	125	N/A
9/30/2023	357	33	15	125	N/A
6/30/2023	347	38	-6	96	N/A
3/31/2023	327	23	-31	78	N/A
12/31/2022	330	25	-35	53	N/A
9/30/2022	302	44	-120	12	N/A
6/30/2022	296	36	-126	15	N/A
3/31/2022	314	51	-110	24	N/A
12/31/2021	311	63	-96	43	N/A
9/30/2021	345	79	14	67	N/A
6/30/2021	311	69	-28	43	N/A
3/31/2021	269	61	-72	18	N/A
12/31/2020	244	64	-81	2	N/A
9/30/2020	235	61	-85	-16	N/A
6/30/2020	244	76	27	73	N/A
3/31/2020	258	85	85	121	N/A
12/31/2019	264	120	107	168	N/A
12/31/2018	151	45	-23	51	N/A
12/31/2017	53	-23	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688222's forecast earnings growth (22% per year) is above the savings rate (2.9%).

Earnings vs Market: 688222's earnings (22% per year) are forecast to grow slower than the CN market (23.7% per year).

High Growth Earnings: 688222's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688222's revenue (19.5% per year) is forecast to grow faster than the CN market (13.5% per year).

High Growth Revenue: 688222's revenue (19.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688222's Return on Equity is forecast to be low in 3 years time (4.6%).

HitGen Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 41%

Price target increased by 22% to CN¥23.00

Consensus revenue estimates fall by 17%

Price target increased to CN¥18.90

Price target decreased to CN¥28.50

Recent updates

Optimistic Investors Push HitGen Inc. (SHSE:688222) Shares Up 51% But Growth Is Lacking

New minor risk - Share price stability

HitGen Inc. to Report Q3, 2024 Results on Oct 26, 2024

Now 20% overvalued

Now 25% overvalued

HitGen Inc. (SHSE:688222) Shares Could Be 26% Above Their Intrinsic Value Estimate

HitGen Inc. to Report First Half, 2024 Results on Aug 29, 2024

HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly

HitGen Inc., Annual General Meeting, May 22, 2024

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.02 loss in 1Q 2023)

HitGen Inc. to Report Q1, 2024 Results on Apr 25, 2024

Now 23% undervalued

HitGen Inc.'s (SHSE:688222) 28% Jump Shows Its Popularity With Investors

Full year 2023 earnings: EPS exceeds analyst expectations

Third quarter 2023 earnings released

New minor risk - Share price stability

Consensus EPS estimates fall by 41%

Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0 in 2Q 2022)

HitGen Inc. to Report Q2, 2023 Results on Aug 23, 2023

HitGen Inc. Launches A Newly Upgraded Version of OpenDEL™, A Self-Service Screening Kit, to Facilitate Innovative Drug Discovery Research

Price target increased by 22% to CN¥23.00

First quarter 2023 earnings released: CN¥0.02 loss per share (vs CN¥0.02 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 17%

Price target increased to CN¥18.90

Third quarter 2022 earnings released: EPS: CN¥0.052 (vs CN¥0.02 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0 (vs CN¥0.06 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥28.50

Full year 2021 earnings: EPS and revenues miss analyst expectations

Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.02 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.01 (vs CN¥0.02 in 1Q 2020)

Cocrystal Pharma, Inc. Extends Drug Discovery Collaboration with HitGen and InterX, Inc

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.33 in FY 2019)

Revenue behind estimates

HitGen and UPPTHERA Entera Into Drug Discovery Research Collaboration

New 90-day high: CN¥40.13

New 90-day low: CN¥29.19

HitGen Announces License Agreement With Merck & Co., Inc., Kenilworth, NJ USA to Access Compounds for Potential Development of Novel Class of Drugs

Cedilla Therapeutics, Inc. and HitGen Inc. Announces Research Collaboration Focused on Dna-Encoded Library Based Drug Discovery

HitGen Licenses its Trk/ROS1 Inhibitor HG030 to Baiyunshan for Development and Commercialisation in China

New 90-day low: CN¥31.33

HitGen Inc. to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low: CN¥36.33

HitGen Inc. (SHSE:688222) agreed to acquire Vernalis (R&D) Limited from Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) for $25 million.

New 90-day low: CN¥37.61

New 90-day low - CN¥38.20

First half earnings released

New 90-day low - CN¥40.30

HitGen Inc. to Report First Half, 2020 Results on Aug 21, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies